Journal of Medicinal Chemistry
Brief Article
(2) Bajzar, L.; Manuel, R.; Nesheim, M. E. Purification and
characterization of TAFI, a thrombin-activable fibrinolysis inhibitor.
J. Biol. Chem. 1995, 270, 14477−14484.
(3) Bouma, B. N.; Meijers, J. C. M. Thrombin-activatable fibrinolysis
inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase
R, procarboxypeptidase U). J. Thromb. Haemostasis 2003, 1, 1566−
1574.
(4) Vercauteren, E.; Gils, A.; Declerck, P. J. Thrombin activatable
fibrinolysis inhibitor: a putative target to enhance fibrinolysis. Semin.
Thromb. Hemostasis 2013, 4, 365−372.
(19) Polla, M. O.; Tottie, L.; Norden, C.; Linschoten, M.; Musil, D.;
̈
Trumpp-Kallmeyer, S.; Aukrust, I. R.; Ringom, R.; Holm, K. H.; Neset,
S. M.; Sandberg, M.; Thurmond, J.; Yu, P.; Hategan, G.; Anderson, H.
Design and synthesis of potent orally active, inhibitors, inhibitors of
carboxypeptidase U (TAFIa). Bioorg. Med. Chem. 2004, 12, 1151−
1175.
(20) Barrow, J. C.; Nantermet, P. G.; Stauffer, S. R.; Ngo, P. L.;
Steinbeiser, M. A.; Mao, S.-S.; Carroll, S. S.; Balley, C.; Colussi, D.;
Bosserman, M.; Burlein, C.; Cook, J. J.; Sitko, G.; Tiller, P. R.; Miller-
Stein, C. M.; Rose, M.; McMasters, D. R.; Vacca, J. P.; Selnick, H. G.
Synthesis and evaluation of imidazole acetic acid inhibitors of activated
thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. J.
Med. Chem. 2003, 46, 5294−5297.
(5) (a) Fernandez, D.; Pallares, I.; Covaleda, G.; Aviles, F. X.;
Vendrell, J. Metallocarboxypeptidases and their inhibitors: recent
developments in biomedically relevant protein and organic ligands.
Curr. Med. Chem. 2013, 20, 1595−1608. (b) Willemse, J. L.; Heylen,
E.; Nesheim, M. E.; Hendriks, D. F. Carboxypeptidase U (TAFIa): a
new drug target for fibrinolytic therapy? J. Thromb. Haemostasis 2009,
7, 1962−1971. (c) Vercauteren, E.; Peeters, M.; Hoylaerts, M. F.;
Lijnen, H. R.; Meijers, J. C. M.; Declerck, P. J.; Gils, A. The
hyperfibrinolytic state of mice with combined thrombin-activatable
fibrinolysis (TAFI) and plasminogen activator inhibitor1 gene
deficiency is critically dependent on TAFI deficiency. J. Thromb.
Haemostasis 2012, 10, 2555−2562.
(21) Hendrickx, M. L. V.; Zatloukalova, M.; Hassanzadeh-Ghassabeh,
G.; Muyldermans, S.; Gils, A.; Declerck, P. J. Identification of a novel,
nanobody induced, mechanism of TAFI inactivation and its in vivo
application. J. Thromb. Haemostasis 2014, 12, 229−236.
(22) Semeraro, F.; Ammollo, C. T.; Gils, A.; Declerck, P. J.; Coluccci,
M. Monoclonal antibodies targeting the antifibrinolytic activity of
activated thrombin-activatable fibrinolysis inhibitor but not the anti-
inflammatory activity on osteopontin and C5a. J. Thromb. Haemostasis
2013, 11, 2137−2147.
(23) Kallus, C.; Broenstrup, M.; Czechtizky, W.; Evers, A.; Follmann,
M.; Halland, N.; Schreuder, H. Urea and sulfamide derivatives as tafia
inhibitors. WO 2008067909, 2008.
́
(6) Hendriks, D.; Scharpe, S.; van. Sande, M.; Lommaert, M. P.
Characterisation of a carboxypeptidase in human serum distinct from
carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 1989, 27, 277−285.
(7) Campbell, W.; Okada, H. An arginine specific carboxypeptidase
generated in blood during coagulation or inflammation which is
unrelated to carboxypeptidase N or its subunits. Biochem. Biophys. Res.
Commun. 1989, 162, 933−939.
(24) Kalaitzis, J. A.; Lauro, F. M.; Neilan, B. A. Mining cyanobacterial
genomes for genes encoding complex biosynthetic pathways. Nat.
Prod. Rep. 2009, 26, 1447−1465.
(25) Niedermayer, T.; Broenstrup, M. Natural Product Drug Discovery
from Microalgae, Microalgal Biotechnology; Posten, C., Walter, C., Eds.;
Walter de Gruyter: Berlin, 2012; pp 169−202.
(8) Tan, A. K.; Eaton, D. L. Activation and characterization of
procarboxypeptidase B from human plasma. Biochemistry 1995, 34,
5811−5816.
(26) Leao, P. N.; Engene, N.; Antunes, A.; Gerwick, W. H.;
̃
Vasconcelosac, V. The chemical ecology of cyanobacteria. Nat. Prod.
Rep. 2012, 29, 372−391.
(9) Christianson, D. W.; Lipscomb, W. N. Carboxypeptidase A. Acc.
Chem. Res. 1989, 22, 62−69.
(27) Murakami, M.; Suzuki, S.; Itou, Y.; Kodani, S.; Ishida, K. New
anabaenopeptins, potent carboxypeptidase-A inhibitors from the
cyanobacterium aphanizomenon flos-aquae. J. Nat. Prod. 2000, 63,
1280−1282.
́
(10) Vendrell, J.; Querol, E.; Aviles, F. X. Metallocarboxypeptidases
and their protein inhibitors. Structure, function and biomedical
properties. Biochim. Biophys. Acta 2000, 1477, 284−298.
(11) Jensen, A. F.; Burkrinsky, J. T.; Bjerrum, M. J.; Larsen, S. Three
high-resolution crystal structures of cadmium-substituted carboxypep-
tidase A provide insights into enzymatic function. J. Biol. Inorg. Chem.
2002, 7, 490−499.
(28) Itou, Y.; Suzuki, S.; Ishida, K.; Murakami, M. Anabaenopeptins
G and H, potent carboxypeptidase A inhibitors from the
cyanobacterium Oscillatoria agardhii (NIES-595). Bioorg. Med. Chem.
Lett. 1999, 9, 1243−1246.
(12) Wang, Y.-X.; Zhao, L.; Nagashima, M.; Vincelette, J.; Sukovich,
D.; Li, W.; Subramanyam, B.; Yuan, S.; Emayan, K.; Islam, I.; Hrvatin,
P.; Bryant, J.; Light, D. R.; Vergona, R.; Morser, J.; Buckman, B. O. A
novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor
(TAFIa)Part I: Pharmacological characterization. J. Thromb.
Haemostasis 2007, 97, 45−53.
(13) Wang, Y.-X.; da Cunha, V.; Vincelette, J.; Zhao, L.; Nagashima,
M.; Kawai, K.; Yuan, S.; Emayan, K.; Islam, I.; Hosoya, J.; Sullivan, M.
E.; Dole, W. P.; Morser, J.; Buckman, B. O.; Vergona, R. A novel
inhibitor of activated thrombin activatable fibrinolysis inhibitor
(TAFIa)Part II: Enhancement of both exogenous and endogenous
fibrinolysis in animal models of thrombosis. J. Thromb. Haemostasis
2007, 97, 54−61.
(29) Bjorquist, P.; Buchanan,M.; Campitelli, M.; Carroll, A.; Hyde,
̈
E.; Neve, J.; Polla, M.; Quinn, R. Use of cyclic anabaenopeptin-type
peptides for the treatment of a condition wherein inhibition of
carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and
intermediates thereof. WO2005039617, 2005.
(30) Boffa, M. B.; Wang, W.; Bajzar, L.; Nesheim, M. E. Plasma and
recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and
activated TAFI compared with respect to glycosylation, thrombin/
thrombomodulin-dependent activation, thermal stability, and enzy-
matic properties. J. Biol. Chem. 1998, 273, 2127−2135.
(31) Marx, P. F.; Harma, T.; Brondijk, C.; Plug, T.; Romijn, R. A.;
Hemrika, W.; Meijers, J. C. M.; Huizinga, E. G. Crystal structure of
TAFI elucidate the inactivation mechanism of activated TAFI: a novel
mechanism for enzyme autoregulation. Blood 2008, 112, 2803−2809.
(32) Anand, K.; Pallares, I.; Valnickova, Z.; Christensen, T.; Vendrell,
(14) Polla, M.Chemical compounds. WO 003027128, 2003.
(15) Brink, M.; Dahlen, A.; Olsson, T.; Polla, M.; Svensson, T.
Design and synthesis of conformationally restricted inhibitors of active
thrombin activatable fibrinolysis inhibitor (TAFIa). Bioorg. Med. Chem.
2014, 22, 2261−2268.
́
J.; Wendt, K. U.; Schreuder, H. A.; Enghild, J. J.; Aviles, F. X. The
crystal structure of thrombin-activatable fibrinolysis inhibitor (TAFI)
provides the structural basis for its intrinsic activity and the short half-
life of TAFIa. J. Biol. Chem. 2008, 283, 29416−29423.
(16) Linschoten, M.; Polla, M.; Svenson, P. New compounds.
WO2000066557, 2000.
(17) For general zinc bonding properties of hydroxamic acids, see
Chen, K.; Xu, L.; Wiest, O. Computational exploration of zinc binding
groups for HDAC inhibition. J. Org. Chem. 2013, 78, 5051−5055.
(18) Doo, Y. H.; Gifford-Moore, D. S.; Beight, D. W.; Rathnachalam,
R.; Klimkowski, V. J.; Warshawsky, A. M.; Li, D. Inhibition of
thrombin activatable fibrinolysis inhibitor by cysteine derivatives.
Thromb. Res. 2005, 116, 265−271.
F
J. Med. Chem. XXXX, XXX, XXX−XXX